|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Virginia Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing VirginiaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
CEL-SCI Corporation
| | | Phone: | (703) 506-9460 | Fax: | (703) 506-9471 | Year Established: | 1983 | Ticker: | CVM | Exchange: | AMEX | Main Contact: | Geert Kersten, Director & CEO | | Other Contacts: | Todd S. Burkhart, VP, Manufacturing/Facilities and Commercial Operations William "Brooke" Jones, VP, QA John Cipriano, Senior VP, Regulatory Affairs Eyal Talor, CTO Daniel Zimmerman, Ph.D., Senior VP, Research,
Cellular Immunology Patricia B. Prichep, Senior VP, Operations
| | Company Description | CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine®. In Phase II clinical trials, Multikine was shown to be safe and well tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007. The Company has operations in Vienna, Virginia, and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu. | |
|
|
|
|
|